Articles On Neurotech International (ASX:NTI)

True to its history of reinvention and repurposing, Pharmaust will be renamed Neurizon Therapeutics after shareholders approved the moniker change at Wednesday’s AGM. The new name “combines our focus on neuro-degenerative diseases with the...

Mesoblast expects FDA stem cell drug approval by the first week of January ‘if not earlier’ FDA to Somnomed: ‘do you want the good news or bad news first?’ Neurotech mulls its US options after FDA’s orphan drug decision Orthocell says reve...

Highlights ASX200 falls 0.67%, led by declines in mining and IT sectors. Energy sector rises, driven by oil price surge amid Middle East tensions. Notable movements include gains in Strike Energy and declines in Neurotech Internationa...

The ASX200 has closed 0.67% lower at 8,150 points. Investors have rising concerns about the Middle Eastern conflict and are responding by exiting equities perceived to pose risk. To the sectors, Energy was the strongest performer, up...

A WA listed biotech has failed in its bid to get major backing from the US Food and Drug Administration for its cannabinoid drug therapy aimed at treating neurological disorders in children.

Neurotech International (NTI) has flagged to its shareholders that the FDA hasn’t granted its product NTI164 orphan drug status. Orphan drug status is that classification awarded to drugs by the FDA for, often, rare diseases. Companies...

Australia’s clinical trials sector generated $1.6bn for the nation’s economy in 2022 according to MTPConnect PharmAust is currently undertaking a Phase 1 open label extension study at two sites in Australia Dimerix has seven Australian sit...

MTPConnect said Australia has a global reputation as a ‘go to’ destination to conduct clinical trials Sector generated $1.6bn for the Australia economy in 2022, up by more than 4% on 2019 figures Argenica said cost to conduct trials in Aus...

  ASX slips  as US jobs data fuels Wall Street panic Westpac gets a new CEO Newcomers into the ASX200 index include Guzman u Gomez   The ASX stumbled by 0.3% on Monday after the US jobs report fell short on Friday night, causing Wall Str...

  Neurotech reports positive genomic analysis of NTI164 as part of Phase 1/2 PANDAS/PANS trial NTI164 shown to positively modify immune cell function and address gene translation dysregulation Disease-modifying potential of NTI164 may impr...

  Adelong Gold (ASX:ADG) has engaged a new exploration consultant to advance the Adelong Gold Project. Initial soil sampling has revealed promising indications of arsenic and antimony, suggesting potential gold mineralisation. A drilling pr...

ASX 200 up on Friday boosted by strong US GDP and Wall Street gains Star Entertainment gets scathing remarks from regulator Downer EDI and TPG Telecom among the stocks to surge today   The ASX closed 0.58% higher on Friday as investors di...

Over the last few years Neurotech International (ASX: NTI) has been gathering a significant amount of clinical evidence that its product NTI164 is effective in treating multiple neurological disorders in children.

ASX rises circa 0.5pc Consumer stocks in focus this week SGQ and PHX lead small caps   Aussie stocks have closed higher on Monday as IT and retail stocks added strength to sentiment. The S&P/ASX200 closed higher, gaining 36.00 points...

Neurotech to secure one or more strategic partnerships for NTI164 in the US, Europe and Asia Partnerships aim to support clinical, regulatory development, manufacturing and future market launches of NTI164 Neurotech to pursue multiple regi...

Tryptamine’s psilocybin trial indicates potential for treating fibromyalgia Actinogen says Xanamem eases depression but misses cognitive goals PYC reports vision gains using experimental eye drug   Tryptamine’s Phase 2a trial shows promis...

ASX rises on Wednesday after soft June Qtr CPI bump All sectors end higher Small caps led by GTE and SPA   The local benchmark index is back in record territory after extended gains on Wednesday as quarterly inflation data assuaged fea...

  Neurotech reports positive results from extension phase of Phase 1/2 trial of NTI164 to treat Rett Syndrome NTI164 is first broad-spectrum cannabinoid drug therapy to show significant clinical improvement in Rett Syndrome patients All 14...

The cannabis industry is poised for growth, driven by evolving legalisation globally Investment opportunities therefore exist across the sector We take a look at the ASX weed stock winners over the past month    The cannabis industry is c...

There are currently no approved treatments available to help children with Autism Spectrum Disorder (ASD). Our biotech Investment Neurotech International (ASX: NTI) is looking to change this.

ASX 200 closes 0.16pc lower after modest rally from morning lows  Six of 11 sectors lower, after rate-sensitive sectors improve after lunch  Killi Resources surges again with a late surge to dethrone Infini   Local markets have trimmed...

Neurotech reports further benefits from Phase 2/3 trial of NTI164 in autism patients Patients showed 56% improvement in CGI-S score from baseline at week 12 Patients unblinded at end of week eight showed 21% improvement in CGI-S score to w...

ASX 200 pointing to a lower start  NVDA adds another 2% as more Wall St records tumble Base metals mostly fell overnight    Aussie markets might have to wallow in red for a bit this morning, despite more of the same in terms of fresh reco...

ASX 200 rises strongly on Tuesday, closes up +0.86pc  All 11 sectors in the green, like Kermit on a golf course  Top small cap was Killi Resources with a bumper +83.7pc surge   Local markets jumped on Tuesday, erasing all of Monday’s l...

  Neurotech International to establish expert PANDAS/PANS Advisory Group Advisory group follows productive pre-submission meeting with TGA NTI’s lead drug NTI164 is showing promise in treatment of PANDAS/PANS   Special Report: Neurotech I...

Aussie stocks start the week flat; energy and tech sectors lead declines Investor caution prevails ahead of RBA rates decision Chinese Premier Li Qiang meets PM in Canberra today   Aussie stocks had a lacklustre start to the week on Monda...

  Neurotech International says ASD patients in its Phase 1/2 trial of NTI164 have now been on treatment for more than two years Initial positive results of the Phase 1/2 ASD trial have been a catalyst for the Phase 2/3 ASD study NTI164 is...

Aussie shares rally Rate sensitive stocks gain, led by Tech FTL soars on Newfoundland deal   Aussie shares climbed strongly on Thursday closing above 7,820 as major global central banks began to cut interest rates and in the US, the S&amp...

Neurotech reports improvements in PANDAS/PANS patients after 52 weeks of NTI164 treatment The study highlights the safety profile of NTI164 and its potential as a therapy for the disease Caregivers express gratitude for significant progres...

ASX starts June positively, extending May gains  Property prices in Australia rose by 0.8% in May, with Sydney remaining the most expensive city Lovisa plunges by -10% as John Cheston takes over as CEO   The ASX has started the month of...

Bell Potter says biotech very much a non-cyclical performer driven by catalysts including clinical trial data Radiopharmaceutical-focused Clarity Pharmaceuticals has risen 76% YTD after promising trial results Merchant Funds is bullish on...

Our biotech Investment, Neurotech International (ASX: NTI) just announced additional data from its Rett Syndrome clinical trial today.

A listed Australian biopharmaceutical development company says it has the potential to provide the world’s first approved cannabinoid drug therapy for neurological disorders, like autism, in children.

  The ASX close higher as unemployment rate came in lower than expected Miners rally, led by BHP as the giant released its Q3 report Nimy Resources up 50pc after reporting promising intercepts   The ASX added 0.5% on Thursday as the unemp...

Where are we in terms of US legalisation of cannabis? What about the current legal landscape for cannabis in Australia? We look at the best performing ASX weed stocks this past month   Global weed stocks have been on bumpy ride over the p...

The ASX rebounded from a sluggish start… but wait, it all dipped again as we were heading out the door Local traders were initially shaken this morning after remarks from Fed’s Powell Aussie defence budget to be given a $50bn boost   The...

Neurotech’s NTIRTT1 becomes first clinical trial to show statistically significant clinical improvement in Rett Syndrome patients with a broad-spectrum cannabinoid drug Company’s NTI164 compares favourably to DAYBUE, the only FDA-approved...

Today, our biotech Investment Neurotech International (ASX: NTI) announced that BOTH of its clinical trials for Autism Spectrum Disorder (ASD) and Rett Syndrome had met the trials’ primary endpoints.

Neurotech International (ASX:NTI), has attained a new milestone in its clinical trial for Autism Spectrum Disorder (ASD) – as it now confirms its 54th and final patient has completed their last visit for the Phase II/III NTIASD2 clinical tr...

Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has confirmed that the last patient in a Phase II/III NTIASD2 clinical trial for children with autism spectrum disorder (ASD) has completed their final...

  Aussie shares set to rise again after a modest tick up on Wall Street Gold price hit a new high Bank of America’s bullish predictions on gold and copper prices   Aussie shares are set to rise again on Wednesday after Wall Street ticked...

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to detect autism and ADHD. It’s listing on the ASX next Thursday (April 4) under the code BB1. BlinkLab’s development is be...

We are Invested in Neurotech International (ASX: NTI) - a clinical stage biotech company.

Morgans says more money could flow into ASX healthcare sector in 2024 as higher interest rate cycle stabilises Nyrada soars after lead drug candidate demonstrates strong efficacy in reducing secondary brain injury in animal study   Dimerix...

Neurotech International (ASX:NTI) has announced the extension of its Phase 1/2 clinical trial investigating the use of NTI164 in female Rett Syndrome patients and an additional ethics approval.

  Local markets give up early gains then regains them, closing 0.22pc higher Consumer Discretionary stocks offset losses in materials and Energy  Small Caps led by LBT Innovations   It’s hard to stay afloat when BHP sinks to a near nine-m...

12-week Phase I/II clinical trial to treat Rett Syndrome with NTI164 broad spectrum cannabinoid drug therapy extended to 52 weeks All 14 female patients to receive NTI164 under care of Associate Professor Carolyn Ellaway Phase I/II 12 week...

Biopharmaceutical development company Neurotech International (ASX: NTI) has extended a Phase I/II clinical trial investigating the use of NTI164 in female Rett Syndrome patients to 52 weeks. The extension replaces the previous 16-week dura...

Mike Tyson has spoken out against the jailing of cannabis users Iron Mike owns his own cannabis brand called TYSON 2.0 We take a look at the best performing ASX weed stocks over the past month    There are currently at least 3,000 individ...

  ASX200 drops about 0.7pc on Wednesday Consumer Staples craters, as WOW CEO departs Small Caps led by diggers IXR, AW1 and the biopharma Alterity   The ASX200 has ended lower on Wednesday, tracking losses in New York as traders brace – a...